Rowland Rowland A A Dias Dias MM MM Wiese Wiese MD MD Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer Br J Cancer Br J Cancer 2015 2015 112 112 1888 1888 1894 1894 10.1038/bjc.2015.173 10.1038/bjc.2015.173 supplied-pmid 25989278? This evidence concerns the gene BRAF and metastatic colorectal cancer.